-
Je něco špatně v tomto záznamu ?
Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis
M. Brejcha, M. Stoklasová, Y. Brychtová, A. Panovská, K. Štěpanovská, G. Vaňková, K. Plevová, A. Oltová, K. Horká, Š. Pospíšilová, J. Mayer, M. Doubek,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu srovnávací studie, hodnotící studie, časopisecké články, práce podpořená grantem
Grantová podpora
NT13493
MZ0
CEP - Centrální evidence projektů
- MeSH
- aktivace lymfocytů účinky léků MeSH
- chronická lymfatická leukemie genetika patologie MeSH
- dospělí MeSH
- hybridizace in situ fluorescenční * MeSH
- interleukin-2 farmakologie MeSH
- klonální evoluce * MeSH
- lidé středního věku MeSH
- lidé MeSH
- oligodeoxyribonukleotidy farmakologie MeSH
- prospektivní studie MeSH
- pruhování chromozomů * MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- hodnotící studie MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
Chronic lymphocytic leukemia (CLL) patients may acquire new chromosome abnormalities during the course of their disease. Clonal evolution (CE) has been detected by conventional chromosome banding (CBA), several groups also confirmed CE with fluorescence in situ hybridization (FISH). At present, there are minimal prospective data on CE frequency determined using a combination of both methods. Therefore, the aim of our study was to prospectively assess CE frequency using a combination of FISH and CBA after stimulation with CpG oligonucleotides and interleukin-2. Between 2008 and 2012, we enrolled 140 patients with previously untreated CLL in a prospective trial evaluating CE using FISH and CBA after stimulation. Patients provided baseline and regular follow-up peripheral blood samples for testing. There was a median of 3 cytogenetic examinations (using both methods) per patient. CE was detected in 15.7% (22/140) of patients using FISH, in 28.6% (40/140) using CBA, and in 34.3% (48/140) of patients by combining both methods. Poor-prognosis CE (new deletion 17p, new deletion 11q or new complex karyotype) was detected in 15% (21/140) of patients and was significantly associated with previous CLL treatment (p=0.013). CBA provides more complex information about cytogenetic abnormalities in CLL patients than FISH and confirms that many patients can acquire new abnormalities during the course of their disease in a relatively short time period.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14050746
- 003
- CZ-PrNML
- 005
- 20191010090346.0
- 007
- ta
- 008
- 140401s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.leukres.2013.10.019 $2 doi
- 035 __
- $a (PubMed)24246692
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Brejcha, Martin $7 xx0105595
- 245 10
- $a Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis / $c M. Brejcha, M. Stoklasová, Y. Brychtová, A. Panovská, K. Štěpanovská, G. Vaňková, K. Plevová, A. Oltová, K. Horká, Š. Pospíšilová, J. Mayer, M. Doubek,
- 520 9_
- $a Chronic lymphocytic leukemia (CLL) patients may acquire new chromosome abnormalities during the course of their disease. Clonal evolution (CE) has been detected by conventional chromosome banding (CBA), several groups also confirmed CE with fluorescence in situ hybridization (FISH). At present, there are minimal prospective data on CE frequency determined using a combination of both methods. Therefore, the aim of our study was to prospectively assess CE frequency using a combination of FISH and CBA after stimulation with CpG oligonucleotides and interleukin-2. Between 2008 and 2012, we enrolled 140 patients with previously untreated CLL in a prospective trial evaluating CE using FISH and CBA after stimulation. Patients provided baseline and regular follow-up peripheral blood samples for testing. There was a median of 3 cytogenetic examinations (using both methods) per patient. CE was detected in 15.7% (22/140) of patients using FISH, in 28.6% (40/140) using CBA, and in 34.3% (48/140) of patients by combining both methods. Poor-prognosis CE (new deletion 17p, new deletion 11q or new complex karyotype) was detected in 15% (21/140) of patients and was significantly associated with previous CLL treatment (p=0.013). CBA provides more complex information about cytogenetic abnormalities in CLL patients than FISH and confirms that many patients can acquire new abnormalities during the course of their disease in a relatively short time period.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a pruhování chromozomů $7 D002871
- 650 12
- $a klonální evoluce $7 D060965
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a hybridizace in situ fluorescenční $7 D017404
- 650 _2
- $a interleukin-2 $x farmakologie $7 D007376
- 650 _2
- $a chronická lymfatická leukemie $x genetika $x patologie $7 D015451
- 650 _2
- $a aktivace lymfocytů $x účinky léků $7 D008213
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a oligodeoxyribonukleotidy $x farmakologie $7 D009838
- 650 _2
- $a prospektivní studie $7 D011446
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a hodnotící studie $7 D023362
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Stoklasová, Martina $u - $7 xx0128941
- 700 1_
- $a Brychtová, Yvona $u - $7 xx0105542
- 700 1_
- $a Panovská, Anna $u - $7 xx0137441
- 700 1_
- $a Ďurechová, Kristina $u - $7 xx0246689
- 700 1_
- $a Vaňková, Gabriela $u - $7 _AN074417
- 700 1_
- $a Plevová, Karla $u - $7 xx0158852
- 700 1_
- $a Oltová, Alexandra $u - $7 xx0110415
- 700 1_
- $a Horká, Kateřina $u - $7 _AN038339
- 700 1_
- $a Pospíšilová, Šárka, $u - $d 1969- $7 xx0101843
- 700 1_
- $a Mayer, Jiří, $u - $d 1960- $7 nlk20000083651
- 700 1_
- $a Doubek, Michael, $u - $d 1972- $7 mzk2004217554
- 773 0_
- $w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 38, č. 2 (2014), s. 170-175
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24246692 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140401 $b ABA008
- 991 __
- $a 20191010090805 $b ABA008
- 999 __
- $a ok $b bmc $g 1017882 $s 849326
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 38 $c 2 $d 170-175 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
- GRA __
- $a NT13493 $p MZ0
- LZP __
- $a Pubmed-20140401